Pharvaris (NASDAQ:PHVS) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research started coverage on shares of Pharvaris (NASDAQ:PHVS) in a report released on Thursday morning, Marketbeat reports. The brokerage issued an outperform rating and a $42.00 price target on the stock.

A number of other brokerages have also recently issued reports on PHVS. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wedbush boosted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $27.07 on Thursday. Pharvaris has a 1 year low of $11.51 and a 1 year high of $29.85. The stock has a market capitalization of $1.77 billion, a P/E ratio of -8.03 and a beta of -2.58. The stock has a 50-day simple moving average of $27.06 and a 200-day simple moving average of $25.51.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. Wellington Management Group LLP purchased a new position in shares of Pharvaris during the 3rd quarter valued at approximately $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after buying an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Pharvaris during the 3rd quarter valued at approximately $15,613,000. Commodore Capital LP boosted its stake in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the last quarter.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42.00 price target, implying material upside versus current levels — this can attract buyers and help support the share price. Wolfe Research Initiates Coverage
• Positive Sentiment: Wedbush raised its price target to $42.00, echoing the new analyst optimism and adding another institutional signal that could boost investor interest. Wedbush Increases Price Target
• Positive Sentiment: HC Wainwright reiterated a “Buy” and kept an aggressive $60 price target while materially raising FY2028 and FY2029 EPS forecasts (FY2029 to $1.64), signaling stronger long‑term revenue/profit expectations that could underpin a higher valuation. HC Wainwright Coverage Summary
• Neutral Sentiment: HC Wainwright issued several near‑term EPS tweaks: small downgrades for Q1 and Q2 2026 and slight mix in quarterly estimates — these are modest adjustments (fractions of a dollar) and may temper short‑term sentiment but not necessarily the long‑term thesis. HC Wainwright Quarterly Estimate Changes
• Negative Sentiment: Royal Bank of Canada published a pessimistic forecast for PHVS, which can exert downward pressure by encouraging caution or additional selling from risk‑averse investors. RBC Pessimistic Forecast

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.